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OBJECTIVES: Liver function tests (LFTs) are routinely
requested in primary care often leading to further invasive and
expensive investigations. In patients with raised LFTs without
clinically apparent liver disease the appropriate level of follow-up
can be unclear. The aim was to determine the most cost-effective
GP strategy. METHODS: A retrospective population-based
observational study followed-up all Tayside patients who had
incident LFTs in primary care, with no clinically obvious liver
disease (n = 95,977), to subsequent liver disease diagnosis. Pre-
diction models allowed identiﬁcation of patients at high risk of
liver disease. A decision tree modelled the patient journey from
two main GP decisions—retest or refer to secondary care. Tran-
sition probabilities of retests, referral and liver disease diagnosis
were calculated from biochemistry and liver databases. The
outcome was liver disease diagnosed within one year. Patients
having further investigations carried out at referral were identi-
ﬁed from virology, immunology and pathology datasets. Costs of
investigations in primary and secondary care were obtained from
various sources. Utilities were obtained from systematic review,
and patient survey at the liver clinic at Ninewell’s Hospital,
Dundee. The incremental cost-utility ratio (ICUR) was calcu-
lated. Sensitivity analysis was performed for all parameters.
RESULTS: For the average patient with abnormal LFTs the
retesting strategy dominated referral. However, for patients in
the top percentile of liver disease risk, referral to secondary care
was more cost-effective (ICUR = £7588/year). The average cost
of referral was £11.20 lower per patient than retesting. Retesting
QALY gain was only 0.001. Sensitivity results varied although
referral was in the main more cost-effective. CONCLUSIONS:
This is the ﬁrst cost-utility analysis of GP strategies for patients
with abnormal LFTs. It is more cost-effective to refer patients
with abnormal LFTs who have high risk of liver disease identiﬁed
by the model, whilst those with average risk should be retested in
primary care.
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OBJECTIVES: This study estimates the cost and the effectiveness
of terlipressin and somatostatin in the treatment of bleeding
oesophageal varices (BOV) in Spain. METHODS: A Markov
model was created with the following ﬁve states: patient with
cirrhosis, bleeding, re-bleeding, endoscopy treatment, transjugu-
lar intrahepatic portosystemic shunt, and death. Efﬁcacy data on
survival, re-bleeding and control of bleeding were obtained from
high quality studies reported in Cochrane meta-analyses. Base-
line outcomes related to the course of disease and health-state
utilities were derived from published sources. Treatment costs
and all related BOV costs were obtained from a panel of experts
and published Spanish sources. RESULTS: The average aggre-
gated treatment cost per person for all medical interventions at
5 years was lower for terlipressin-treated patients (€5165)
compared with those treated using somatostatin (€5439). Costs
considered in the study were pharmacologic treatment costs,
laboratory and diagnostic tests costs, specialist consultation costs
and hospitalization costs. All costs are referred to year 2008. The
incremental analysis comparing terlipressin with somatostatin
using a cost per quality adjusted life year (QALY) approach
indicated that terlipressin was the dominant BOV treatment
option (i.e. it cost less and it was more effective). CONCLU-
SIONS: Results from base-case and sensitivity analysis indicate
that terlipressin is a cost-effective treatment for BEV when it is
compared to somatostatin in the Spanish setting.
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OBJECTIVES: To describe the relationship between increasing
intensity of symptoms and reduced work productivity in GERD
patients and effects on cost in a real life primary care setting in
Spain. METHODS: In this retrospective, observational study,
a random sample of all patients visiting a primary health care
center for any reason related to GERD over a 4-month period
were included. Patients were invited to participate, and those
who accepted attended an interview during which clinical data
were collected. Information regarding work productivity was
collected using the Work Productivity and Activity Impairment
questionnaire GERD (WPAI-GERD) and symptoms using the
Reﬂux Disease Questionnaire (RDQ). Both use a 7-day recall
period and are validated questionnaires. RESULTS: Overall,
63,416 patients were identiﬁed during the study period. In 1727
(2.7%) patients GERD was a reason for the visit. Of these, 579
patients were randomly selected and 87% participated in the
study; Mean age was 60 years (SD: 15,7), 59% were women. On
average, patients were absent from work 2.9 hours per week, and
mean work time lost due to reduced productivity was 7.7 hours
per week. The mean monetary value of these productivity losses
was €117.6€ per patient. There was an increase in cost of reduced
productivity as the RDQ score increased: R2: 0.26, 0.23, 0.29
and 0.28 for heartburn, acid regurgitation, GERD and dyspepsia
dimensions, respectively. When patients with high symptom load,
according to frequency and intensity, were studied separately,
coefﬁcients increased to 0.34, 0.34, 0.42 and 0.36, respectively.
The monetary value of productivity losses increased from €3.8€
to €31.0€ and to €132.7€ when heartburn intensity increased
from mild to moderate and to severe, respectively. Likewise,
when acid regurgitation was considered, the increase was from
€7.7€ to 32.47 and to €175.18. CONCLUSIONS: GERD has a
mayor impact on patients’ productivity. Increasing intensity of
symptoms was associated with the increased productivity loss.
GASTROINTESTINAL DISORDERS—Patient-Reported
Outcomes Studies
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OBJECTIVES: To develop the Bowel Cleansing Impact Review
(BOCLIR), a new questionnaire designed to assess patient
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